ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

ProMIS Neurosciences announced positive Phase 1a trial results showing PMN310, its lead Alzheimer's drug candidate, achieved dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid. The company demonstrated target engagement in healthy volunteers and plans to present six-month blinded interim data from its Phase 1b PRECISE-AD trial in the coming weeks, with top-line results expected in early Q1 2027.